Cargando…
Parkinson’s disease clinical milestones and mortality
Identification of factors predicting and driving mortality in PD is important for patient information, disease management, and design of future clinical trials. This study included newly diagnosed PD patients and normal controls (NC) from a population-based study with repeated assessments over a 10-...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098431/ https://www.ncbi.nlm.nih.gov/pubmed/35550520 http://dx.doi.org/10.1038/s41531-022-00320-z |
_version_ | 1784706381529481216 |
---|---|
author | Gonzalez, Maria Camila Dalen, Ingvild Maple-Grødem, Jodi Tysnes, Ole-Bjørn Alves, Guido |
author_facet | Gonzalez, Maria Camila Dalen, Ingvild Maple-Grødem, Jodi Tysnes, Ole-Bjørn Alves, Guido |
author_sort | Gonzalez, Maria Camila |
collection | PubMed |
description | Identification of factors predicting and driving mortality in PD is important for patient information, disease management, and design of future clinical trials. This study included newly diagnosed PD patients and normal controls (NC) from a population-based study with repeated assessments over a 10-year period. We used the Kaplan–Meier method to estimate survival, Cox proportional hazards regression models to identify baseline risk factors of mortality, and Cox regression models with time-dependent covariates to evaluate the impact of four clinical milestones of advanced PD (visual hallucinations, recurrent falls, dementia, and nursing home placement) on mortality risk. During the 10-year study, 65 (34.2%) of 190 patients and 25 (12.3%) of 203 NC died, with an unadjusted hazard ratio (HR) of 2.85 (95% CI 1.80–4.52) and a HR of 2.48 (95% CI 1.55–3.95) when adjusted for confounders, including comorbidities. Higher age, more severe motor impairment, and postural instability-gait difficulty (PIGD) phenotype were independent baseline predictors of mortality. Each clinical milestone alone more than doubled the risk of death and had a cumulative effect on mortality, with a HR of 10.83 (95% CI 4.39–26.73) in those experiencing all four milestones. PD patients have an increased mortality risk that is disease-related and becomes evident early during the course of the disease. While motor severity and PIGD phenotype were early risk factors of mortality, clinical milestones signaled a substantially increased risk of death later during the disease course, highlighting their potential significance in clinical disease staging and prognosis. |
format | Online Article Text |
id | pubmed-9098431 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-90984312022-05-14 Parkinson’s disease clinical milestones and mortality Gonzalez, Maria Camila Dalen, Ingvild Maple-Grødem, Jodi Tysnes, Ole-Bjørn Alves, Guido NPJ Parkinsons Dis Article Identification of factors predicting and driving mortality in PD is important for patient information, disease management, and design of future clinical trials. This study included newly diagnosed PD patients and normal controls (NC) from a population-based study with repeated assessments over a 10-year period. We used the Kaplan–Meier method to estimate survival, Cox proportional hazards regression models to identify baseline risk factors of mortality, and Cox regression models with time-dependent covariates to evaluate the impact of four clinical milestones of advanced PD (visual hallucinations, recurrent falls, dementia, and nursing home placement) on mortality risk. During the 10-year study, 65 (34.2%) of 190 patients and 25 (12.3%) of 203 NC died, with an unadjusted hazard ratio (HR) of 2.85 (95% CI 1.80–4.52) and a HR of 2.48 (95% CI 1.55–3.95) when adjusted for confounders, including comorbidities. Higher age, more severe motor impairment, and postural instability-gait difficulty (PIGD) phenotype were independent baseline predictors of mortality. Each clinical milestone alone more than doubled the risk of death and had a cumulative effect on mortality, with a HR of 10.83 (95% CI 4.39–26.73) in those experiencing all four milestones. PD patients have an increased mortality risk that is disease-related and becomes evident early during the course of the disease. While motor severity and PIGD phenotype were early risk factors of mortality, clinical milestones signaled a substantially increased risk of death later during the disease course, highlighting their potential significance in clinical disease staging and prognosis. Nature Publishing Group UK 2022-05-12 /pmc/articles/PMC9098431/ /pubmed/35550520 http://dx.doi.org/10.1038/s41531-022-00320-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Gonzalez, Maria Camila Dalen, Ingvild Maple-Grødem, Jodi Tysnes, Ole-Bjørn Alves, Guido Parkinson’s disease clinical milestones and mortality |
title | Parkinson’s disease clinical milestones and mortality |
title_full | Parkinson’s disease clinical milestones and mortality |
title_fullStr | Parkinson’s disease clinical milestones and mortality |
title_full_unstemmed | Parkinson’s disease clinical milestones and mortality |
title_short | Parkinson’s disease clinical milestones and mortality |
title_sort | parkinson’s disease clinical milestones and mortality |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098431/ https://www.ncbi.nlm.nih.gov/pubmed/35550520 http://dx.doi.org/10.1038/s41531-022-00320-z |
work_keys_str_mv | AT gonzalezmariacamila parkinsonsdiseaseclinicalmilestonesandmortality AT daleningvild parkinsonsdiseaseclinicalmilestonesandmortality AT maplegrødemjodi parkinsonsdiseaseclinicalmilestonesandmortality AT tysnesolebjørn parkinsonsdiseaseclinicalmilestonesandmortality AT alvesguido parkinsonsdiseaseclinicalmilestonesandmortality |